A 62-year-old woman with idiopathic cardiomyopathy and class IIIB/stage C heart failure sustained right pulmonary artery injury from a Swan-Ganz catheter during a pretransplant work up. Postprocedure, it was noted that the patient's segmental pulmonary artery catheter was wedged for an unclear period of time. The patient developed a small volume of blood-tinged sputum and a chest CT revealed a 1.3 cm pseudoaneurysm in the right middle lobe medial segment pulmonary artery and a small area of haemorrhage. The patient underwent pulmonary artery preserving coil embolisation of the pseudoaneurysm to prevent further right heart strain, given an ejection fraction of 20%, which resolved haemoptysis. Imaging studies showed preserved distal outflow and no evidence of residual pseudoaneurysm filling.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636702 | PMC |
| http://dx.doi.org/10.1136/bcr-2015-212555 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Initial therapy in patients with pulmonary arterial hypertension and cardiovascular comorbidities.
Eur Respir J
January 2025
INSERM UMR_S 999 « Pulmonary Hypertension: Pathophysiology and Novel Therapies », Hôpital Marie Lannelongue, Le Plessis-Robinson, France
Background: European guidelines recommend initial monotherapy in PAH patients with cardiovascular (CV) comorbidities based on the limited of evidence for combination therapy in this growing population.
Methods: A retrospective analysis was conducted on incident PAH patients enrolled in the French Pulmonary Hypertension Registry between 2009 and 2020. Propensity score matching was used to investigate initial dual oral combination therapy oral monotherapy in patients with at least one CV comorbidity (, hypertension, obesity, diabetes and coronary artery disease).
Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies.
Eur Respir J
January 2025
Université Paris-Saclay, INSERM Unité Mixte de Recherche en Santé 999 (HPPIT), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre (Assistance Publique-Hôpitaux de Paris), Le Kremlin-Bicêtre, France.
Introduction: Pulmonary arterial hypertension (PAH) is a progressive disease associated with significant morbidity and mortality. Sotatercept is a first-in-class activin signalling inhibitor that acts to restore the balance between the growth-promoting and growth-inhibiting signalling pathways.
Methods: This post-hoc, exploratory, pooled analysis combines data from the double-blind placebo periods of the phase 2 PULSAR (NCT03496207) and phase 3 STELLAR (NCT04576988) studies.
Subdermal contraceptive implant migration to pulmonary artery branch.
BMJ Case Rep
January 2025
Radiology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.
Subdermal contraceptive implants are now commonly used throughout the world. One of the rare complications of these implants is migration to the lungs due to misplacement of the implant during insertion, with only a limited number of cases documented. Here, we present a case where a subdermal contraceptive implant embolised in the subsegmental branch of the pulmonary artery within the anterobasal segment of the left lower lobe.
View Article and Find Full Text PDFTHE INDIVIDUAL FIBRINOLYTIC CAPACITY PREDICTS EFFICACY OF ULTRASOUND-ASSISTED CATHETER-DIRECTED THROMBOLYSIS IN PATIENTS WITH ACUTE PULMONARY EMBOLISM.
J Thromb Haemost
January 2025
Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Background: Ultrasound-assisted catheter-directed thrombolysis (USAT) is nowadays available as an alternative reperfusion approach for acute pulmonary embolism (PE). The lytic agent recombinant tissue-type plasminogen activator (rt-PA) activates the effector protease plasmin to induce fibrinolysis. The aim of this study was to identify predictive markers for the efficacy of USAT in patients with acute PE.
View Article and Find Full Text PDFUnlocking insights: Clinical associations from the largest 6-minute walk test collection via the my Heart Counts Cardiovascular Health Study, a fully digital smartphone platform.
Prog Cardiovasc Dis
January 2025
Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Wu Tsai Human Performance Alliance, Stanford University School of Medicine, Stanford, CA 94305, USA; Center for Digital Health, Stanford University School of Medicine, Stanford, CA 94305, USA; Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address:
Background: The six-minute walk test (6MWT) is a prognostic sub-maximal exercise test used clinically as a measure of functional capacity. With the emergence of advanced sensors, 6MWTs are being performed remotely via smartphones and other devices. The My Heart Counts Cardiovascular Health Study is a smartphone application that serves as a digital platform for studies of human cardiovascular health, and has been used to perform 30,475 6MWTs on 8922 unique participants.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!